患有和未患有抗核抗体的不孕妇女首次接受辅助生殖技术治疗的结果：前瞻性队列研究

IF 2.1 4区医学 Q2 OBSTETRICS & GYNECOLOGY

European journal of obstetrics, gynecology, and reproductive biology Pub Date : 2024-11-23 DOI:10.1016/j.ejogrb.2024.11.030

Menglu Wu , Shan Kang , Yaqiu Wang , Guiliang Hao , Mingran Wu , Mingzhen Guo , Lin Zhao , Shuai Wang , Sen Wang , Cuifang Hao , Jinlian Song

{"title":"患有和未患有抗核抗体的不孕妇女首次接受辅助生殖技术治疗的结果：前瞻性队列研究","authors":"Menglu Wu , Shan Kang , Yaqiu Wang , Guiliang Hao , Mingran Wu , Mingzhen Guo , Lin Zhao , Shuai Wang , Sen Wang , Cuifang Hao , Jinlian Song","doi":"10.1016/j.ejogrb.2024.11.030","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>It has been shown that antinuclear antibodies (ANAs) are associated with adverse reproductive events. The presence of ANAs may reduce the pregnancy rate in women undergoing assisted reproductive technology (ART) treatment.</div></div><div><h3>Methods</h3><div>This study aimed to investigate the potential effect of ANAs on the outcomes of infertile women undergoing in-vitro fertilization and embryo transfer (IVF-ET) or intracytoplasmic sperm injection (ICSI) for the first time. In total, 907 women were enrolled, with 192 (21.14 %) cases in the ANA+ group and 715 (78.86 %) cases in the ANA- group. Baseline data were collected, and associations between ANAs and oocyte maturation rate, high-quality embryo rate, clinical pregnancy rate, live birth rate and miscarriage rate were analysed.</div></div><div><h3>Results</h3><div>Compared with the ANA- group, the ANA+ group had a considerably lower oocyte maturation rate (0.69 ± 0.31 vs 0.77 ± 0.26; <em>P</em> = 0.003) and a lower high-quality embryo rate (0.53 ± 0.30 vs 0.78 ± 0.92; <em>P</em> < 0.01). ANAs had no effect on clinical pregnancy rate, live birth rate and miscarriage rate in infertile women receiving ART for the first time.</div></div><div><h3>Conclusions</h3><div>These findings suggest that ANAs reduce oocyte maturation rate and high-quality embryo rate in infertile women undergoing IVF-ET/ICSI for the first time, but do not have a significant effect on clinical pregnancy rate, live birth rate and miscarriage rate. When testing for ANAs is part of the planned treatment protocol, this should be undertaken in advance of starting IVF-ET/ICSI.</div></div>","PeriodicalId":11975,"journal":{"name":"European journal of obstetrics, gynecology, and reproductive biology","volume":"304 ","pages":"Pages 85-89"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of first assisted reproductive technology treatment in infertile women with and without antinuclear antibodies: A prospective cohort study\",\"authors\":\"Menglu Wu , Shan Kang , Yaqiu Wang , Guiliang Hao , Mingran Wu , Mingzhen Guo , Lin Zhao , Shuai Wang , Sen Wang , Cuifang Hao , Jinlian Song\",\"doi\":\"10.1016/j.ejogrb.2024.11.030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>It has been shown that antinuclear antibodies (ANAs) are associated with adverse reproductive events. The presence of ANAs may reduce the pregnancy rate in women undergoing assisted reproductive technology (ART) treatment.</div></div><div><h3>Methods</h3><div>This study aimed to investigate the potential effect of ANAs on the outcomes of infertile women undergoing in-vitro fertilization and embryo transfer (IVF-ET) or intracytoplasmic sperm injection (ICSI) for the first time. In total, 907 women were enrolled, with 192 (21.14 %) cases in the ANA+ group and 715 (78.86 %) cases in the ANA- group. Baseline data were collected, and associations between ANAs and oocyte maturation rate, high-quality embryo rate, clinical pregnancy rate, live birth rate and miscarriage rate were analysed.</div></div><div><h3>Results</h3><div>Compared with the ANA- group, the ANA+ group had a considerably lower oocyte maturation rate (0.69 ± 0.31 vs 0.77 ± 0.26; <em>P</em> = 0.003) and a lower high-quality embryo rate (0.53 ± 0.30 vs 0.78 ± 0.92; <em>P</em> < 0.01). ANAs had no effect on clinical pregnancy rate, live birth rate and miscarriage rate in infertile women receiving ART for the first time.</div></div><div><h3>Conclusions</h3><div>These findings suggest that ANAs reduce oocyte maturation rate and high-quality embryo rate in infertile women undergoing IVF-ET/ICSI for the first time, but do not have a significant effect on clinical pregnancy rate, live birth rate and miscarriage rate. When testing for ANAs is part of the planned treatment protocol, this should be undertaken in advance of starting IVF-ET/ICSI.</div></div>\",\"PeriodicalId\":11975,\"journal\":{\"name\":\"European journal of obstetrics, gynecology, and reproductive biology\",\"volume\":\"304 \",\"pages\":\"Pages 85-89\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of obstetrics, gynecology, and reproductive biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0301211524006420\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of obstetrics, gynecology, and reproductive biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301211524006420","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景已有研究表明，抗核抗体（ANAs）与不良生殖事件有关。本研究旨在调查 ANA 对首次接受体外受精和胚胎移植（IVF-ET）或卵胞浆内单精子注射（ICSI）的不孕妇女的潜在影响。共有 907 名妇女参加了该研究，其中 ANA+ 组有 192 例（21.14%），ANA- 组有 715 例（78.86%）。结果与 ANA- 组相比，ANA+ 组的卵母细胞成熟率（0.69 ± 0.31 vs 0.77 ± 0.26; P = 0.003）和优质胚胎率（0.53 ± 0.30 vs 0.78 ± 0.92; P <0.01）明显较低。结论：这些研究结果表明，ANA 会降低首次接受 IVF-ET/ICSI 的不孕妇女的卵母细胞成熟率和优质胚胎率，但对临床妊娠率、活产率和流产率没有显著影响。如果 ANA 检测是计划治疗方案的一部分，则应在开始 IVF-ET/ICSI 前进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcomes of first assisted reproductive technology treatment in infertile women with and without antinuclear antibodies: A prospective cohort study

Background

It has been shown that antinuclear antibodies (ANAs) are associated with adverse reproductive events. The presence of ANAs may reduce the pregnancy rate in women undergoing assisted reproductive technology (ART) treatment.

Methods

This study aimed to investigate the potential effect of ANAs on the outcomes of infertile women undergoing in-vitro fertilization and embryo transfer (IVF-ET) or intracytoplasmic sperm injection (ICSI) for the first time. In total, 907 women were enrolled, with 192 (21.14 %) cases in the ANA+ group and 715 (78.86 %) cases in the ANA- group. Baseline data were collected, and associations between ANAs and oocyte maturation rate, high-quality embryo rate, clinical pregnancy rate, live birth rate and miscarriage rate were analysed.

Results

Compared with the ANA- group, the ANA+ group had a considerably lower oocyte maturation rate (0.69 ± 0.31 vs 0.77 ± 0.26; P = 0.003) and a lower high-quality embryo rate (0.53 ± 0.30 vs 0.78 ± 0.92; P < 0.01). ANAs had no effect on clinical pregnancy rate, live birth rate and miscarriage rate in infertile women receiving ART for the first time.

Conclusions

These findings suggest that ANAs reduce oocyte maturation rate and high-quality embryo rate in infertile women undergoing IVF-ET/ICSI for the first time, but do not have a significant effect on clinical pregnancy rate, live birth rate and miscarriage rate. When testing for ANAs is part of the planned treatment protocol, this should be undertaken in advance of starting IVF-ET/ICSI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European journal of obstetrics, gynecology, and reproductive biology 医学-妇产科学

CiteScore

4.60

自引率

3.80%

发文量

898

审稿时长

8.3 weeks

期刊介绍： The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. It publishes peer reviewed original research articles, as well as a wide range of news, book reviews, biographical, historical and educational articles and a lively correspondence section. Fields covered include obstetrics, prenatal diagnosis, maternal-fetal medicine, perinatology, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine, infertility, reproductive endocrinology, sexual medicine and reproductive ethics. The European Journal of Obstetrics & Gynecology and Reproductive Biology provides a forum for scientific and clinical professional communication in obstetrics and gynecology throughout Europe and the world.